Tidal ETF Trust II The Meet Kevin Pricing Power ETF (ARCA: PP)

Dernières nouvelles pour Tidal ETF Trust II The Meet Kevin Pricing Power ETF (ARCA:PP)

Technology

Consumer Cyclical

Industrials

Basic Materials

The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by investing primarily in the U.S.-listed equity securities of Innovative Companies (defined below). The Fund categorizes an Innovative Company as a company determined by the Funds sub-adviser, Platos Philosophy LLC (the Sub-Adviser), to be involved in the development of new products or services, technological advancements, consumer engagement, and/or disruptive approaches with respect to business growth that the Sub-Adviser expects to have a significant impact on the market or industry in which the company operates. Further, the Fund will invest in Innovative Companies that, in the Sub-Advisers view, also have more pricing power than their peers. The Sub-Adviser generally analyzes pricing power based on price elasticity, which is the ability to potentially increase prices for products and services without a corresponding drop in demand. In addition, the Fund may hold the securities of other ETFs, which could be passively-managed or actively-managed (Targeted ETFs) to seek to hedge (provide protection for the Funds portfolio) against particular market risks anticipated by the Sub-Adviser.

First American Government Obligations Fund

Tesla Inc.

Apple Inc Aapl

Amazon.Com Inc

NVIDIA Corporation

The Trade Desk Inc

Enphase Energy Inc.

Taiwan Semiconductor Manufacturing Company Limited

Asml Holding Nv (new York Registered)

Advanced Micro Devices Inc.

The Meet Kevin Pricing Power ETF

Tidal ETF Trust II The Meet Kevin Pricing Power ETF

Invesco Aerospace & Defense ETF

PT PERUSAHAAN GAS NEGARA by PT Perusahaan Gas Negara Persaro

PT Perusahaan Gas Negara Tbk

PT PERUSAHAAN GS UNSP/ADR by PT Perusahaan Gas Negara Persaro

PEOPLES TR CO ST ALBNS VT by Peoples Trust Co.

Peoples Trust Company Of St. Albans

PICK N PAY STORES LTD by Pick n' Pay Stores Ltd.

Pick N Pay Stores Ltd

Plasma Finance

PEOPLES BANCORP WASH by Peoples Bancorp Wash

Peoples Bancorp Wash

Pacific Premier Bancorp Inc - Common Stock

Pacific Premier Bancorp Inc

PACIFIC PREMIER BANCORP ORD

PINNACLE BANKSHARES CORP by Pinnacle Bankshares Corp.

Pinnacle Bankshares Corp

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech Ltd

PURPLE BEVERAGE CO INC by Purple Beverage Co., Inc.

Purple Beverage Co Inc

Pilgrim's Pride Corporation - Common Stock

Pilgrims Pride Corp

Peercoin

PROPANC BIOPHARMA INC by Propanc Biopharma, Inc.

Propanc Biopharma Inc

PICC PPTY&CASUALTY ORD H by PICC Property and Casualty Co., Ltd.

PICC Property and Casualty Co Ltd

PICC PPTY&CSLT UNSP/ADR H by PICC Property and Casualty Co., Ltd.

MOLECULAR ENERGIS PLC by MOLECULAR ENERGIES PLC

Molecular Energies PLC

PPC Ltd

PREMIER PAC CONSTR INC by Premier Pacific Construction, Inc.

FINVOLUTION GROUP ADR

Putnam ETF Trust Putnam PanAgora ESG Emerging Markets Equity ETF

PAMPA ENERGIA SA ORD by Pampa Energia S.A.

Pampa Energia SA

PT BK MANDIRI PERSERO ORD by PT Bank Mandiri Persero TBK

PT Bank Mandiri (Persero) Tbk

PT BK MANDIR PRS UNSP/ADR by PT Bank Mandiri Persero TBK

Olivier Ventures Inc

OLIVIER VENTURES INC by Olivier Ventures Inc.

PPG Industries Inc

VanEck Pharmaceutical ETF

POSITIVE PHYSICIANS HLDGS by Positive Physicians Holdings, Inc.

Positive Physicians Holdings Inc

PHP Ventures Acquisition Corp

PHP Ventures Acquisition Corp.

PHP VENTURES ACQUISITION CORP RT

PHP Ventures Acquisition Corp Units (1 Ord Class A & 1/2 War & 1 Right)

PHP Ventures Acquisition Corp Warrants (01/01/2023)

AXS Astoria Real Assets ETF

Putnam ETF Trust Putnam PanAgora ESG International Equity ETF

Perma-Pipe International Holdings, Inc. - Common Stock

Perma-Pipe International Holdings Inc

Coenzyme A Inc

PT PANTAI INDAH KAPUK DUA by PT PANTAI INDAH KAPUK DUA TBK

PHILIPPINE NATL BK by Philippine National Bank

Philippine National Bank

PPJ HEALTHCARE ENTERPRISE by PPJ Healthcare Enterprises, Inc.

PPJ Healthcare Enterprises Inc

PEPKOR HOLDINGS LTD. by Pepkor Holdings Ltd.

Pepkor Holdings Ltd

PT PABRIK KERTAS TJW KIMA by PT Pabrik Kertas Tjiwi Kimia Tbk

PT Pabrik Kertas Tjiwi Kimia Tbk

PPL Corp

PEMBINA PIPLNE CL A PFD 5 by Pembina Pipeline Corp.

Pembina Pipeline Corp

PT PERUSAHAAN GAS NGR ORD by PT Perusahaan Perkebunan London Sumatra Indonesia Tbk

PT PP London Sumatra Indonesia Tbk

PT PERUSAHAAN UNSP/ADR by PT Perusahaan Perkebunan London Sumatra Indonesia Tbk

Peoples Ltd

PEMBINA PIPELINE PFD A by Pembina Pipeline Corp.

abrdn Physical Platinum Shares ETF

PROTIDE PHARMS INC by Protide Pharmaceuticals, Inc.

POINT TO POINT METHODICS by Point to Point Methodics, Inc.

Point To Point Methodics Inc

PROFIT PLANNERS MGMT NEW by Profit Planners Management, Inc.

Profit Planners Management Inc

PGE POLSKA GRUPA ENER ORD by PGE Polska Grupa Energetyczna SA

Polska Grupa Energetyczna SA

PGE POLSKA GRUPA ENERGETYCZNA ORD

PT CHAROEN POKPHAND IND by PT Charoen Pokphand Indonesia Tbk

PT Charoen Pokphand Indonesia Tbk

PATIENT PORTAL TECHS INC by Patient Portal Technologies, Inc.

Patient Portal Technologies Inc

Choice Properties Real Estate Investment Trust

ProntoForms Corp

Kering SA

KERING ORD

PREMIER PWR RENEWABLE ENG by Premier Power Renewable Energy, Inc.

Premier Power Renewable Energy Inc

PUSHPAY HLDGS UNSP/ADR by Pushpay Hldgs Ltd.

Pioneer Power Solutions, Inc. - Common Stock

Pioneer Power Solutions Inc

Putnam Premier Income Trust

Populous

Perpetua Resources Corp

PeptiDream Inc

PREMIUM ENERGY CORP by Premium Energy Corp.

Perpetual Ltd

U.S. Diversified Real Estate ETF

PacifiCorp

Papaya Growth Opportunity Corp. I - Class A Common Stock

Papaya Growth Opportunity Corp I

Papaya Growth Opportunity Corp. I - Warrant

SEASIF EXPLORATION INC by SEASIF EXPLORATION INC.

Seasif Exploration Inc

Earnings

News

XPON

Expion360 Q3 EPS $(24.55) Up From $(26.25) YoY; Revenue $1.389M Down From $1.890M YoY

DBGI

Digital Brands Group Q3 EPS $(1.63), Sales $2.44M Down From $3.26M YoY

ZURA

Zura Bio Announces Submission Of Protocol To FDA For Phase 2 Study Of Tibulizumab In Adults With Systemic Sclerosis

Offerings

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Files For Offer And Resale By Selling Stockholders Of Up To 1,577,829 Shares Of Common Stock

Q4 2024 Guidance
<ul>
<li>Net Sales are expected to range between $13.5 - $14.0 million</li>
<li>Gross Margin is expected to be in the range of 22.0% - 25.0%</li>
<li>Operating Expenses are expected to be in a range of $(5.5) - $(6.5) million</li>
</ul>

Guidance

DFLI

Dragonfly Energy Sees Q4 2024 Net Sales $13.5M-$14M

Trading Ideas

CTRI

13F Shows Carl Icahn Added Stake In Centuri Holdings With 1,000,000 Shares

The company has entered into a securities purchase agreement with certain new and existing institutional investors for the purchase of an aggregate of&nbsp;17.50 million common shares of the Company, without par value, and accompanying Class B warrants to purchase up to an aggregate of 8.75 million Common Shares in a registered direct offering.&nbsp;

The Metals Company Plans $17.5M Direct Offering Of Common Shares And Class B Warrants

Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.79) by 49.37 percent. The company reported quarterly sales of $3.860 million which missed the analyst consensus estimate of $4.061 million by 4.95 percent. This is a 16.93 percent increase over sales of $3.301 million the same period last year.

Earnings Beats

Earnings Misses

VVOS

Vivos Therapeutics Q3 2024 GAAP EPS $(0.40) Beats $(0.79) Estimate, Sales $3.860M Miss $4.061M Estimate

OMNIQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMQS#NASDAQ">OMQS</a>) reported quarterly losses of $(0.15) per share. This is a 72.73 percent increase over losses of $(0.55) per share from the same period last year. The company reported $18.55 million in sales this quarter. This is a 7.57 percent increase over sales of $17.24 million the same period last year.

OMQS

OMNIQ Q3 EPS $(0.15) Up From $(0.55) YoY, Sales $18.55M Up From $17.24M YoY

Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. The company reported quarterly sales of $2.612 million which beat the analyst consensus estimate of $1.240 million by 110.56 percent. This is a 214.32 percent increase over sales of $831.000 thousand the same period last year.

OMGA

Omega Therapeutics Q3 2024 GAAP EPS $(0.30) Misses $(0.28) Estimate, Sales $2.612M Beat $1.240M Estimate

Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.18) by 38.89 percent. The company reported quarterly sales of $12.72 million which missed the analyst consensus estimate of $14.15 million by 10.09 percent. This is a 19.94 percent decrease over sales of $15.89 million the same period last year.

Dragonfly Energy Hldgs Q3 2024 GAAP EPS $(0.11) Beats $(0.18) Estimate, Sales $12.72M Miss $14.15M Estimate

Management

Omega Therapeutics Appoints Kaan Certel As CEO; Succeeds Mahesh Karande

WIIM

RSLS

ReShape Lifesciences shares are trading lower. The company reported Q3 financial results.

HALO

Halozyme Confirms Proposal To Combine With Evotec For €11/Share All-Cash Transaction

Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>) will be unveiling its second-quarter earnings on Friday, <a href="https://www.benzinga.com/quote/BABA/earnings">before market hours</a>. Wall Street is expecting $2.10 in EPS and $33.95 billion in revenue, per <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data.
This comes as the Chinese e-commerce giant faces mounting competition from rivals like JD.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) and Pinduoduo Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), as well as a challenging macroeconomic environment that has tempered consumer spending in China.
Still, some analysts are optimistic that Alibaba&#8217;s growing international digital commerce and cloud segments could drive meaningful results, particularly as the company looks to diversify its revenue sources beyond the domestic market.
With Alibaba's core and cloud divisions in focus, investors hope for upbeat numbers amid a challenging economic climate in China.
<h2 class="wp-block-heading">Alibaba Chart Signals Hints At A Challenging Road Ahead</h2>
From a technical analysis perspective, Alibaba's stock currently reflects a bearish sentiment. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14125936/Screenshot-2024-11-14-at-11.14.05-PM.png" alt="" class="wp-image-648695" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14125936/Screenshot-2024-11-14-at-11.14.05-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14125936/Screenshot-2024-11-14-at-11.14.05-PM-300x218.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111424&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Read Also: <a href="https://www.benzinga.com/news/global/24/11/41889911/whats-going-on-with-china-based-stocks-alibaba-jd-com-pdd-holdings-baidu-nio">What&#8217;s Going On With China-Based Stocks Alibaba, JD.com, PDD Holdings, Baidu, Nio?</a>
Trading at $90.32, BABA stock sits below several key moving averages, including its five, 20 and 50-day exponential moving averages, suggesting a continuation of selling pressure in the near term. BABA stock trades below its eight-day Simple Moving Average (SMA) of $94.97 and its 20-day SMA of $97.39, reinforcing these bearish signals. 
The Moving Average Convergence/Divergence (MACD) reading of a negative 2.01 supports a downward trend, though the Relative Strength Index (RSI) of 36.61 hints that Alibaba stock could be in the oversold territory soon. 
This could offer a short-term relief rally, but the technical signals broadly imply caution leading into the earnings report.
<h2 class="wp-block-heading">Analyst Ratings, Price Targets Signal Optimism Despite Challenges</h2>
Despite the near-term technical indicators, analysts hold an overall positive outlook on Alibaba, with a consensus Buy rating. The average analyst price target of $120 suggests a <a href="https://www.benzinga.com/quote/BABA/analyst-ratings">potential upside of 32.86%</a> from current levels. 
The anticipated growth in Alibaba's cloud and international commerce could be the drivers that could help Alibaba navigate the current economic uncertainties.
In the broader context, Alibaba has shown resilience with a 20.83% gain year-to-date, although it has seen a 16.21% decline over the past month, reflecting investor caution ahead of the earnings. 
With the Chinese economy in flux and competitive pressures high, all eyes will be on Alibaba's guidance for the upcoming quarters. If Alibaba can deliver strong growth in its cloud and international businesses, it could signal a turnaround, potentially setting the stage for a stock price rebound. 
As Alibaba navigates these dynamics, Friday's earnings report will be pivotal in determining if this bullish narrative holds.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41902202/trumps-china-hawks-rumored-for-top-roles-yuan-hits-3-month-low">Chinese Currency Hits 3-Month Low: Trump&#8217;s Anti-China Cabinet Appointments Rattle Investors</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Tech

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Alibaba Earnings Could Offer Clues On Challenging Climate: Why Bearish Signals Loom Over China Stock

Contracts

POCI

Precision Optics Secures Initial $340K Production Order From A Large, Global Medical Device Company For New Single-use Ophthalmic Endoscope

ETSY

LBRDA

MTCH

Elliott Investment Management 13F Shows Increased Put Position In Select Sector SPDR Energy ETF From 14,500,000 To 22,600,000 Shares; Increased Stake In Match Group By 3% From 11,705,013 To 12,054,832 Shares; Etsy By 11% From 4,500,000 To 5,000,000 Shares; Put Position In Ishares Russell 2000 ETF By 25% From 1,000,000 To 1,250,000 Shares; Liberty Broadband Corp By 9% From 2,192,858 To 2,384,481 Shares; Western Digital Corp By 90% From 1,185,000 Shares To 2,250,000 Shares

<ul>
<li>Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO&#x2122; I trial for c-MYC in HCC; Company exploring strategic partnership opportunities for Phase 2 development of OTX-2002 
<ul>
<li>Company is focusing capital resources on three prioritized programs that reflect Omega's unique value proposition to enable precision epigenomic control for potential therapeutic advantages versus existing modalities</li>
</ul>
</li>
</ul>

Biotech

General

Omega Therapeutics Completes Phase 1 MYCHELANGELO I Clinical Trial And A Strategic Prioritization Of Its Pipeline

Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.56) by 33.93 percent. This is a 63 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $1.46 million which beat the analyst consensus estimate of $1.14 million by 27.72 percent. This is a 17.42 percent increase over sales of $1.24 million the same period last year.

PSTV

Plus Therapeutics Q3 EPS $(0.37) Beats $(0.56) Estimate, Sales $1.46M Beat $1.14M Estimate

Collectively, these new biomarkers will further improve the clinical utility of AVISE CTD, providing clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys.

Exagen Reports Validation, Regulatory Submission For Approval Of New Systemic Lupus Erythematosus And Rheumatoid Arthritis Biomarkers, To Be Incorporated Into AVISE CTD Platform

Comments

Tidal ETF Trust II The Meet Kevin Pricing Power ETF

Actualités

Dernières nouvelles pour Tidal ETF Trust II The Meet Kevin Pricing Power ETF (ARCA:PP)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL